Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Merck AG Switzerland | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Prolonged anti CD20 therapy for the treatment of active multiple sclerosis leading to continuous B cell depletion is associated with hypogammaglobulinemia predisposing to a potentially increased risk of serious infections, particularly in the more disabled and aged patients. No data have been published on the sequential use of anti CD20 therapies and cladribine, that is thought to act as an immune reconstitution agent. his study aims at investigating IgG and IgM serum concentration changes at 6 and 12 months after switching to cladribine in patients previously treated with anti CD20 therapies (ie, ocrelizumab ≥1.8 gr or rituximab 3.0 gr) for ≥18 months, as compared to continued anti CD20 therapies.
The study population will include patients with remitting relapsing multiple sclerosis consulting the Multiple Sclerosis Center of Neurocenter of Southern Switzerland.
Enrolled patients will have 5 Study Visits, one every 3 months according to clinical practice. At visits at 3 and 6 months only adverse events will be collected for study purposes. Clinical assessments will be performed at baseline, Month 6 and Month 12. Clinical assessments correspond to medical exams performed routinely in MS patients treated with anti CD20 or cladribine therapy: clinical assessments, monitoring haemoglobin parameters, serum immunoglobulins, liver and renal function.(6, 12 months), radiological disability progression and biomarker of ongoing neurodegeneration (12 months).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CLAD-GROUP | Patients with cladribine therapy |
| |
| CD20-GROUP | Patients with anti CD20 therapy (ocrelizumab or rituximab) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cladribine Oral Tablet | Drug | Treatment according to the label and medical prescription |
|
| Measure | Description | Time Frame |
|---|---|---|
| Changes in IgG serum concentrations in Cald-Group | Standard laboratory test | 6 months |
| Changes in IgM serum concentrations in Cald-Group | Standard laboratory test | 6 months |
| Changes in IgG serum concentrations in Clad-Group | Standard laboratory test | 12 months |
| Changes in IgM serum concentrations in Clad-Group | Standard laboratory test | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in IgG serum concentrations after switching to cladribine, as compared to continued anti CD20 therapies | Standard laboratory test | 6 months |
| Changes in IgM serum concentrations after switching to cladribine, as compared to continued anti CD20 therapies |
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of infections | Safety endpoint | 6 months |
| Frequency of infections | Safety endpoint | 12 months |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with relapsing multiple sclerosis
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Claudio Gobbi, MD | Ospedale Regionale di Lugano, Neurocentro della Svizzera italiana, Centro Sclerosi multipla | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano | Lugano | Canton Ticino | 6903 | Switzerland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D017338 | Cladribine |
| D000069283 | Rituximab |
| C533411 | ocrelizumab |
| ID | Term |
|---|---|
| D015762 | 2-Chloroadenosine |
| D000241 | Adenosine |
| D011684 | Purine Nucleosides |
| D011687 | Purines |
Not provided
Not provided
Not provided
Not provided
Not provided
| Rituximab | Drug | Treatment according to the label and medical prescription |
|
|
| Ocrelizumab | Drug | Treatment according to the label and medical prescription |
|
|
Standard laboratory test |
| 6 months |
| Changes in IgG serum concentrations after switching to cladribine, as compared to continued anti CD20 therapies | Standard laboratory test | 12 months |
| Changes in IgM serum concentrations after switching to cladribine, as compared to continued anti CD20 therapies | Standard laboratory test | 12 months |
| Proportion of patients reaching NEDA -3 | NEDA -3: no relapses, no disability progression, no new/enlarging or Gd enhancing brain or spinal MR lesions | 12 months |
| Annualized relapse rate (ARR) over 12 months after switching to cladribine as compared to patients continuing anti CD20 therapies | ARR will be calculated based on recorded number of relapses | 12 months |
| Proportion of patients with disability progression | Expanded disability scale 0-6 (6 worst outcome) | 6 months |
| Proportion of patients with disability progression | Expanded disability scale 0-6 (6 worst outcome) | 12 months |
| Number/volume of cumulative new T2/ enlarging lesions at brain and spinal MRI over 12 months after switching to cladribine, as compared to patients continuing anti CD20 therapies | Evaluation of MRI | 12 months |
| Number/volume of cumulative Gd enhancing lesions at brain and spinal MRI over 12 months after switching to cladribine, as compared to patients continuing anti CD20 therapies | Evaluation of MRI | 12 months |
| Changes in serum neurofilament light chain concentration | single-molecule array (Simoa) assay | 12 months |
| Intensity of infections | Safety endpoint, intensity will be rated according to the following definitions: Mild: Awareness of a sign or symptom that does not interfere with the study participant's usual activity or is transient, resolved without treatment and with no sequelae; Moderate: Interferes with the study participant's usual activity and/or requires symptomatic treatment; Severe: Symptom(s) causing severe discomfort and significant impact of the study participant's usual activity and requires treatment. Serious: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, or is otherwise considered as medically important. | 6 months |
| Intensity of infections | Safety endpoint, intensity will be rated according to the following definitions: Mild: Awareness of a sign or symptom that does not interfere with the study participant's usual activity or is transient, resolved without treatment and with no sequelae; Moderate: Interferes with the study participant's usual activity and/or requires symptomatic treatment; Severe: Symptom(s) causing severe discomfort and significant impact of the study participant's usual activity and requires treatment. Serious: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, or is otherwise considered as medically important. | 12 months |
| Proportion of patients with abnormal creatinine values of clinical relevance | Safety endpoint | 6 months |
| Proportion of patients with abnormal creatinine values of clinical relevance | Safety endpoint | 12 months |
| Proportion of patients with abnormal ASAT values of clinical relevance | Safety endpoint | 6 months |
| Proportion of patients with abnormal ASAT values of clinical relevance | Safety endpoint | 12 months |
| Proportion of patients with abnormal ALAT values of clinical relevance | Safety endpoint | 6 months |
| Proportion of patients with abnormal ALAT values of clinical relevance | Safety endpoint | 12 months |
| Proportion of patients with any abnormal hematology values of clinical relevance | Safety endpoint | 6 months |
| Proportion of patients with any abnormal hematology values of clinical relevance | Safety endpoint | 12 months |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D006574 |
| Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D003839 | Deoxyadenosines |
| D003853 | Deoxyribonucleosides |
| D009705 | Nucleosides |
| D009706 | Nucleic Acids, Nucleotides, and Nucleosides |
| D012263 | Ribonucleosides |
| D058846 | Antibodies, Monoclonal, Murine-Derived |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |